CryoCath Introduces Arctic Front in Australia

Toronto Stock Exchange Symbol: CYT

Mar 26, 2008, 01:00 ET from CryoCath Technologies Inc.

    MONTREAL, March 26 /PRNewswire-FirstCall/ - CryoCath(R) Technologies
 Inc., the global leader in cryotherapy products to treat cardiac
 arrhythmias, today announced the introduction of Arctic Front(R) in
 Australia. Arctic Front, the company's lead product for the treatment of
 paroxysmal atrial fibrillation (PAF), is a unique cryoablation balloon
 catheter that allows physicians to safely and effectively isolate all four
 pulmonary veins to stop PAF.
     On March 13 and 14, a group of nine Australian electrophysiologists
 attended the training program for the Arctic Front system in Melbourne,
 Australia. Leadership of this program was in the hands of Dr. Jeff Alison,
 Head of Electrophysiology and Pacing of the Monash Medical Centre in
 Melbourne, Australia, and Dr. Yves Van Belle of the Thorax Centrum at the
 Erasmus University in Rotterdam, The Netherlands. Dr. Van Belle is one of
 the most experienced users of the Arctic Front system and the author of the
 first publication on this groundbreaking device in a peer reviewed journal.
 Dr. Alison has received training on the system both in Germany as well as
 in Montreal. He has also performed the first Arctic Front procedure in
 Australia in late 2007.
     "Arctic Front holds the promise of a breakthrough therapy in the
 treatment of paroxysmal atrial fibrillation. The data out of Europe
 strongly supports this belief and we're excited to be able to offer a
 potentially safer and effective treatment to our patients," said Dr.
 Alison. "Thousands of Australians suffer from the symptoms of PAF, and a
 safe and effective therapy can bring a substantial benefit to these
     Solid professional education is the foundation of a successful
 introduction of a new technology. In the first Arctic Front Masters Program
 (AFMP) held in Australia, nine physicians from two centers were trained on
 the new technology. As part of the curriculum, they observed two successful
 procedures performed by Dr. Alison. Through the efforts of Life Systems
 Medical Inc., CryoCath's exclusive distributor in Australia, an extensive
 follow-up training program was completed. As a result of this successful
 program, several first Arctic Front procedures were performed in two
 further hospitals across Australia over the past few days.
     "We're happy to see the rapid growth in the use of Arctic Front now
 expanding beyond Europe. The rapidly increasing body of positive clinical
 evidence for the Arctic Front system gives us great confidence that we can
 continue to show a fast expansion of our user base," said Jan Keltjens,
 President and CEO of CryoCath. "I am impressed with the efforts of Life
 Systems Medical and the support from thought leaders in Australia. Well
 over 2,000 patients across 34 centres in Europe have been treated to date
 with Arctic Front. The introduction in Australia will further accelerate
 this momentum and bring the benefits of this breakthrough therapy to large
 groups of patients."
     About CryoCath
     CryoCath - - is a medical technology company that
 leads the world in cryotherapy products to treat cardiac arrhythmias. With
 a priority focus on providing physicians with a complete solution of
 catheter products to treat cardiac arrhythmias, CryoCath has multiple
 products approved in the U.S., across Europe and several ROW countries. The
 Company is developing additional products to expand its pipeline of
 products to treat cardiac arrhythmias.
     This press release includes "forward-looking statements" that are
 subject to risks and uncertainties, including with respect to the timing of
 regulatory trials and their outcome. For information identifying
 legislative or regulatory, economic, climatic, currency, technological,
 competitive and other important factors that could cause actual results to
 differ materially from those anticipated in the forward-looking statements,
 see CryoCath's annual report available at under the heading
 Risks and Uncertainties in the Management's Discussion and Analysis

SOURCE CryoCath Technologies Inc.